- Home
- ANGH vs GOVX Comparison
ANGH vs GOVX Comparison
Compare ANGH & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- GOVX
- Stock Information
- Founded
- ANGH 2012
- GOVX 2001
- Country
- ANGH United Arab Emirates
- GOVX United States
- Employees
- ANGH N/A
- GOVX N/A
- Industry
- ANGH Telecommunications Equipment
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- GOVX Health Care
- Exchange
- ANGH Nasdaq
- GOVX Nasdaq
- Market Cap
- ANGH 19.1M
- GOVX 16.8M
- IPO Year
- ANGH N/A
- GOVX N/A
- Fundamental
- Price
- ANGH $2.95
- GOVX $0.57
- Analyst Decision
- ANGH
- GOVX Strong Buy
- Analyst Count
- ANGH 0
- GOVX 3
- Target Price
- ANGH N/A
- GOVX $10.67
- AVG Volume (30 Days)
- ANGH 7.2K
- GOVX 1.3M
- Earning Date
- ANGH 11-07-2025
- GOVX 11-11-2025
- Dividend Yield
- ANGH N/A
- GOVX N/A
- EPS Growth
- ANGH N/A
- GOVX N/A
- EPS
- ANGH N/A
- GOVX N/A
- Revenue
- ANGH $78,093,405.00
- GOVX $6,143,044.00
- Revenue This Year
- ANGH N/A
- GOVX N/A
- Revenue Next Year
- ANGH N/A
- GOVX N/A
- P/E Ratio
- ANGH N/A
- GOVX N/A
- Revenue Growth
- ANGH 88.72
- GOVX 1943.07
- 52 Week Low
- ANGH $2.53
- GOVX $0.43
- 52 Week High
- ANGH $9.40
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- ANGH 51.60
- GOVX 46.65
- Support Level
- ANGH $2.53
- GOVX $0.52
- Resistance Level
- ANGH $2.94
- GOVX $0.61
- Average True Range (ATR)
- ANGH 0.10
- GOVX 0.04
- MACD
- ANGH 0.00
- GOVX 0.01
- Stochastic Oscillator
- ANGH 89.33
- GOVX 46.55
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.